age-related macular degeneration

News

Phase 3 readout puts Opthea at risk of insolvency

After its lead wet AMD drug failed a phase 3 trial, Opthea may have to make massive repayments to investors that would threaten its viability.

News

Ophthalmologists' phoropter for eye exams

FDA changes its mind on Astellas' geographic atrophy drug

Astellas has shored up the competitive profile of Izervay for eye disorder geographic atrophy, getting FDA approval for extended treatment.

News

FDA says no to Astellas' geographic atrophy drug

Astellas has suffered another major setback with geographic atrophy (GA) treatment Izervay, this time in the US.

News

NICE backs first ophthalmic bevacizumab for NHS use

Outlook Therapeutics' Lytenava has become the first ophthalmic formulation of VEGF inhibitor bevacizumab to be cleared for use by the NHS in England and Wales for treating wet age-related m

News

winking smiley face on paper held in front of a woman's face

Astellas pulls geographic atrophy drug filing in the EU

Astellas confirmed today that it will withdraw its EMA filing for avacincaptad pegol as a treatment for eye disorder geographic atrophy (GA), based on feedback from the EU regulator.

News

Roche will relaunch AMD implant Susvimo after update

Roche’s Genentech unit has said will reintroduce its Susvimo implant for eyesight-robbing disease age-related macular degeneration (AMD), which was withdrawn from sale in 2022 due to manufa

Phase 3 readout puts Opthea at risk of insolvency

FDA changes its mind on Astellas' geographic atrophy drug

FDA says no to Astellas' geographic atrophy drug

NICE backs first ophthalmic bevacizumab for NHS use

Astellas pulls geographic atrophy drug filing in the EU

Roche will relaunch AMD implant Susvimo after update

Novo sues Lilly over 'misleading' GLP-1 ad campaigning

Discover a new era of healthcare panel engagement: Grounded ...

age-related macular degeneration

Editor's Picks